ARCHIVES

In Congress: $135 Million Expected For DOD Breast Cancer Research Program

This article is from The Cancer Letter archive.

Vol. 24 No. 29 | July 24, 1998

Download PDF Visit The Full Archive

Related Articles

NSABP’s B-14 Study Reports Deaths From Uterine Cancer Related To Tamoxifen

February 25, 1994

Carbone Heads Chairmen’s Group

June 30, 1978

FDA Approves Xeloda For Breast Cancer After Failure Of Anthracycline Treatment.

September 28, 2001

DCPC BSC Committee Endorses Three Research Concepts

April 17, 1987

Docetaxel As Adjuvant Therapy Shows Benefit Over Standard

June 28, 2002

DCPC Advisors Okay Omnibus Prevention Program Announcement

January 24, 1992